BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after ...
If we want to understand how we arrived in this authoritarian moment in 2025, we need to understand one of the central ...
Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, today announced new data from the company's ...
Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in ...
Get ready for an explosive streaming week (Oct 20-26, 2025)! It's packed with action They Call Him OG, sci-fi Elevation, ...
How is understanding the Rangarajan Line relevant to the UPSC exam? What significance do topics like Gold ETF, GST reduction, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback